Advertisement

Topics

PubMed Journals Articles About "Pharma Incorporated" RSS

07:47 EDT 25th March 2019 | BioPortfolio

Pharma Incorporated PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Pharma Incorporated articles that have been published worldwide.

More Information about "Pharma Incorporated" on BioPortfolio

We have published hundreds of Pharma Incorporated news stories on BioPortfolio along with dozens of Pharma Incorporated Clinical Trials and PubMed Articles about Pharma Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharma Incorporated Companies in our database. You can also find out about relevant Pharma Incorporated Drugs and Medications on this site too.

Showing "Pharma Incorporated" PubMed Articles, all 24

Establishing and Maintaining a Robust Sample Management System.

This paper has been written by the SLAS Sample Management Special Interest Group to serve as a guide to the best practices and methods in establishing and maintaining a high-quality sample management system. The topics covered are applicable to sample types ranging from small molecules to biologics to tissue samples. It has been put together using the collective experience of the authors in start-up companies, small pharma, agricultural research, IT, academia, biorepositories, and large pharma companies. Ou...


Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.

Research on effectiveness of DAA is limited. Existing researches explore impact of DAA only on relationship between drug manufacturers and consumers. However, in reality, pharma marketing revolves around three major stakeholders: the pharmaceutical companies, physicians and consumers. Pharmaceutical professionals on behalf of drug manufacturers have last mile connectivity with end users and they are an important stakeholder in this entire marketing relationship network. So, it is important for marketers to ...

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ("FDA"). Established chiefly as a command and control federal administrative agency, iterative changes in legislation have shaped the FDA's activity in drug, biologic, and medical device regulation over the course of the last one hundred plus years. The most recent fundamental reframing of the agency's authorit...


CVS and the $100,000 QALY.

The PBM unit of the health giant CVS decided that any new drug exceeding $100,000 per quality-adjusted life year (QALY) may be excluded from the formularies that are maintained by its clients. Patient groups (with the backing of pharma) say that the measure is discriminatory.

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the deadline. Although a majority of the draft guidelines regulating this process were already known in 2014 and 2015, the anticipated process itself caused anxiety among representatives of the foreign pharma industry, who tried to prepare for coming challenges. Among other possible issues, the ambiguity of transition...

Pharma APMs: Can the Industry Learn To Play Well With Others?

The alternative payment model (APM) is a nontraditional financial arrangement that rewards health care providers who deliver cost-effective, high-quality care. Now we are facing the possibility that pharmaceutical manufacturers and insurers will embrace APMs as a payment mechanism in some situations.

Pharmacy-related theft of controlled substances: RxPATROL® findings.

To characterize pharmacy-related theft data reported to the Rx Pattern Analysis Tracking Robberies and Other Losses (RxPATROL®) database during the time periods before (2007-2010) and after (2011-2016) the August 2010 switch to reformulated OxyContin® (oxycodone hydrochloride) extended-release tablets (Purdue Pharma L.P.).

The Complexity of Compliance in Sample Management: A Review of Key Issues Impacting Small-Molecule and Biological Sample Management in Early Drug Discovery.

The discovery of new medicines has become increasingly more challenging and requires significant collaboration between pharma, biotech, academia, and technology to be successful. These partnerships necessitate the streamlined exchange of samples while adhering to the increasingly complex set of legal and proprietary restrictions, government legislation, and ethical considerations associated with samples. There is a significant volume of literature published on clinical sample compliance but little describin...

Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome.

Numerous preclinical studies have supported the theory that enhanced activation of mGluR5 signaling, due to the absence or reduction of the FMR1 protein, contributes to cognitive and behavioral deficits in patients with fragile X syndrome (FXS). However multiple phase 2 controlled trials in patients with FXS have failed to demonstrate efficacy of compounds that negatively modulate mGluR5, including two phase 2b randomized controlled trials (RCT) of mavoglurant (AFQ056, Novartis Pharma AG), when the primary ...

Domino Synthesis of Unsaturated Lactams via Stereoselective Amination of Tertiary Allylic Alcohols.

Tertiary allylic alcohols equipped with a carboxyl group can be smoothly aminated under ambient conditions via a conceptually new and stereoselective protocol under Pd catalysis. The in situ formed (Z)-configured alfa-amino acid cyclizes to afford an alfa,beta-unsaturated gamma-lactam releasing water as the only by-product. This practical catalytic transformation highlights the use of a carboxyl group acting as a hydrogen donor, stereodirecting and functional group to provide a wide series of pharma-relevan...

Untargeted metabolite profiling and phytochemical analysis of Micromeria fruticosa L. (Lamiaceae) leaves.

Micromeria fruticosa is an important crop, is widely used in the Mediterranean basin as food and in folk medicine, owing to its health-promoting properties, partially due to the secondary metabolite composition. However, complete information on the phyto-metabolites in M. fruticosa is still lacking. Plant leaves were extracted in methanol (80%), then the phyto-metabolites were separated on C18 column and an extensive characterization using UHPLC-DAD-ESI-QTOF-MS method in two ionization modes was established...

Medication development: reducing casualties in the valley of death and providing support for survivors.

Ray et al (Ray et al., 2018) discuss several obstacles encountered in the transition from pre-clinical to human clinical testing in the development of novel medications for alcohol use disorders (AUD). A large number of promising drugs have perished in this transition phase, so large that the term "valley of death" has been proposed to characterize this perilous passage (Butler, 2008). Even when the valley of death has successfully been crossed the pathway to marketing remains highly problematic. In a pap...

The innovation ecosystem: an analysis of a decade of approved and failed drugs.

Pharmaceutical companies are relying more often on external sources of innovation to boost their discovery research productivity. However, more in-depth knowledge about how external innovation may translate to successful product launches is still required in order to better understand how to best leverage the innovation ecosystem. We analyzed the pre-approval publication histories for FDA-approved new molecular entities (NMEs) and new biologic entities (NBEs) launched by 13 top research pharma companies dur...

Promoting cannabis products to pharmaceutical drugs.

Cannabis sativa is widely used for medical purposes. However, to date, aroma, popular strain name or the content of two phytocannabinoids-Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD) are mostly considered for therapeutic activity. This is despite the hundreds of compounds in this plant and their potential synergistic interactions in mixtures. New, specific and effective cannabis-based drugs must be developed to achieve adequate medical standards for the use of cannabis. To do this, the comprehensive ...

Gilteritinib: First Global Approval.

Gilteritinib (Xospata) is an orally available small molecule receptor tyrosine kinase inhibitor developed by Astellas Pharma in collaboration with Kotobuki Pharmaceutical for the treatment of acute myeloid leukaemia (AML) harbouring FMS-like tyrosine kinase 3 (FLT3) mutations. Gilteritinib inhibits FLT3 (STK1 or FLK2), AXL (UFO or JTK11) and anaplastic lymphoma kinase (ALK or CD246). Gilteritinib inhibits FLT3 signalling in cells expressing FLT3 internal tandem duplication (ITD), tyrosine kinase domain muta...

Medical populism.

Medical emergencies are staple features of today's 24/7 culture of breaking news. As politics becomes increasingly stylised, audiences fragmented, and established knowledge claims contested, health crises have become even more vulnerable to politicisation. We offer the vocabulary of medical populism to make sense of this phenomenon. We define medical populism as a political style based on performances of public health crises that pit 'the people' against 'the establishment.' While some health emergencies le...

The required coefficient of friction in Parkinson's disease: people with freezing of gait.

The required coefficient of friction (RCOF) is frequently reported in the literature as an indicator of slip propensity, a consequence of the collisional aspect of legged locomotion. Little is known about the RCOF in pathological gait. Therefore, this study aimed to quantify the RCOF in subjects with Parkinson's disease (PD) and freezing of gait (FOG) during the OFF-pharma phase, and to investigate the interplay between RCOF parameters and ankle kinematic and kinetic gait variables. Fourteen subjects with P...

Genome mining for the search and discovery of bioactive compounds: The Streptomyces paradigm.

The need for new antimicrobials is indisputable. The flight from natural products in drug discovery was unfortunate. However, the revolution that is genome mining, enabled by the explosion in sequencing technology, is a cause for hope. Nevertheless, renewed search and discovery is still a challenge. We explore novel metabolite diversity and the challenges in Streptomyces. Estimating novel bioactive metabolites remaining to be discovered is an important driver for future investment. Frequent re-discovery of ...

Establishment of a CFD-based k a model in microtiter plates to support CHO cell culture scale-up during clone selection.

Microtiter plates are a common tool for clone selection in biopharmaceutical development. A way of visualizing and evaluating these systems and key processes parameters is the application of Computational Fluid Dynamics (CFD). CFD is a powerful tool for the modelling of hydrodynamics and mass transfer parameters. In this work, CFD was used to determine the specific surface area, the volumetric power input and the oxygen mass transfer coefficient k a for two different microtiter plates with different scales ...

Defense potential of secondary metabolites in medicinal plants under UV-B stress.

Ultraviolet-B (UV-B) radiation has, for many decades now, been widely studied with respect to its consequences on plant and animal health. Though according to NASA, the ozone hole is on its way to recovery, it will still be a considerable time before UV-B levels reach pre-industrial limits. Thus, for the present, excessive UV-B reaching the Earth is a cause for concern, and UV-B related human ailments are on the rise. Plants produce various secondary metabolites as one of the defense strategies under UV-B. ...

Optimizing Non-bonded Interactions of the OPLS Force Field for Aqueous Solutions of Carbohydrates: How to Capture Both Thermodynamics and Dynamics.

Knowledge on thermodynamic and transport properties of aqueous solutions of carbohydrates is of great interest for process and product design in the food, pharma- ceutical, and biotechnological industries. Molecular simulation is a powerful tool to calculate these properties, but current classical force fields cannot provide accurate es- timates for all properties of interest. The poor performance of the force fields is mainly observed for concentrated solutions, where solute-solute interactions are overest...

Randomized clinical trial to evaluate the efficacy of prostaglandin F to treat purulent vaginal discharge in lactating dairy cows.

The objectives of this study were (1) to assess the effect of purulent vaginal discharge (PVD) on reproductive performance using a 4-point vaginal discharge score (VDS) and (2) to evaluate the effect of PGF treatment in cows with PVD on reproductive performance. Holstein cows (n = 2,473) from 1 commercial dairy farm had their vaginal discharge scored at 32 ± 3 d in milk (DIM) using a 4-point scale. Cows were also scored for body condition score and had their ovaries examined using transrectal ultrasound. A...

Modelling pharmaceutical emissions and their toxicity-related impacts in life cycle assessment (LCA) - A review.

Over the last few decades, worldwide detection of active pharmaceutical ingredients (APIs) in aquatic environments and the associated toxicological effects on wildlife and human health have become a matter of public and scientific debate. While life cycle assessment (LCA) and life cycle impact assessment (LCIA) models are increasingly used to assess the potential eco- and human-toxicological impacts of chemical emissions, few studies have looked into the issue of modelling pharmaceutical emissions specifica...

Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.

As part of its Single Technology Appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer (EUSA Pharma) of dinutuximab beta (Qarziba) to submit evidence of its clinical and cost effectiveness for treating neuroblastoma. The BMJ Technology Assessment Group (BMJ-TAG) was commissioned to act as the Evidence Review Group (ERG), reviewing the submission from the company. The Decision Support Unit (DSU) was commissioned to review additional evidence submitt...


Advertisement
Quick Search
Advertisement
Advertisement